AI Article Synopsis

  • The study assessed the long-term effectiveness of thermoablative fractional CO laser (TACO2L) for treating early stress urinary incontinence (SUI) in postmenopausal women.
  • A total of 161 postmenopausal women with mild SUI received TACO2L treatments every 30-45 days, showing significant improvements in urinary function at 12, 24, and 36 months post-treatment.
  • The findings indicate that TACO2L is a safe and effective treatment for mild SUI, though further studies are needed to confirm these long-term benefits.

Article Abstract

Introduction And Hypothesis: The aim of this study was to evaluate the long-term effect of thermoablative fractional CO laser (TACO2L) as an alternative treatment for early stages of stress urinary incontinence (SUI) in postmenopausal women with genitourinary syndrome of menopause.

Methods: A total of 161 postmenopausal patients (age 53.38 ± 5.1 years, range 45-65 years) with a clinical diagnosis of mild SUI were prospectively enrolled in the study. Patients received one treatment with TACO2L every 30-45 days, each treatment comprising four sessions, followed in all patients by a yearly treatment session at 12, 24 and 36 months. SUI was evaluated using the International Continence Society 1-h pad test and the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) before and after TACO2L treatment.

Results: TACO2L treatment was associated with a significant improvement in ICIQ-UI SF scores and 1-h pad weight test at 12 months (both p < 0.001), 24 months (both p < 0.001) and 36 months (both p < 0.001). Improvements were maintained for up to 36 months without the need for any further intervention. The results were confirmed by significant histological changes related to trophic restoration of the vagina, responsible for extrinsic and intrinsic mechanisms involved in urinary continence.

Conclusions: Our results suggest that TACO2L is an efficient and safe novel treatment strategy in patients with mild SUI. Further investigation to confirm the long-term results presented here is still warranted.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780538PMC
http://dx.doi.org/10.1007/s00192-017-3352-1DOI Listing

Publication Analysis

Top Keywords

long-term thermoablative
8
thermoablative fractional
8
fractional laser
8
urinary incontinence
8
women genitourinary
8
genitourinary syndrome
8
1-h pad
8
treatment
6
laser treatment
4
treatment novel
4

Similar Publications

Article Synopsis
  • Microsurgical resection of epilepsy-related lesions carries risks of motor impairment, prompting the exploration of less invasive options like MRI-guided laser interstitial thermal therapy (MRgLITT) which has shown improved neurological outcomes.
  • A case study of a 17-year-old athlete highlighted the use of advanced tractography techniques to map the corticospinal tract (CST), aiding in presurgical planning and guiding the MRgLITT procedure.
  • The integration of CST tractography proved to be effective in enhancing the MRgLITT process, allowing for successful tumor ablation while preserving motor function, although challenges in tractography accuracy and thermal output predictability remain to be addressed.
View Article and Find Full Text PDF

Focused Ultrasound for Treatment of Movement Disorders: A Review of Non-Food and Drug Administration Approved Indications.

Stereotact Funct Neurosurg

April 2024

Department of Neurological Surgery, UCSF, San Francisco, California, USA.

Introduction: MRI-guided focused ultrasound (FUS) is an incisionless thermo-ablative procedure that may be used to treat medication-refractory movement disorders, with a growing number of potential anatomic targets and clinical applications. As of this article's publication, the only US Food and Drug Administration (FDA)-approved uses of FUS for movement disorders are thalamotomy for essential tremor (ET) and tremor-dominant Parkinson's Disease (PD), and pallidotomy for other cardinal symptoms of PD. We present a state-of-the-art review on all non-FDA approved indications of FUS for movement disorders, beyond the most well-described indications of ET and PD.

View Article and Find Full Text PDF

Epilepsy is one of the most common neurological diseases in both adults and children. Despite improvements in medical care, 20 to 30% of patients are still resistant to the best medical treatment. The quality of life, neurologic morbidity, and even mortality of patients are significantly impacted by medically intractable epilepsy.

View Article and Find Full Text PDF

[Nephron sparing in the management of localized solid renal mass].

Bull Cancer

July 2024

AP-HP, hôpital Necker-Enfants-Malades, service d'imagerie adulte, 75015 Paris, France; Université de Paris-Cité, 75006 Paris, France; Sorbonne université, laboratoire d'imagerie biomédicale, CNRS, Inserm, Paris, France.

Article Synopsis
  • - Managing malignant renal tumors requires careful consideration of treatment necessity, factoring in the patient's renal function, risk of chronic kidney disease, and overall survival chances.
  • - Treatment choices vary, focusing on tumor size, location, and the patient's health status, with an emphasis on renal-sparing techniques for small tumors.
  • - Effective management relies on collaboration among urologists, radiologists, nephrologists, and sometimes radiotherapists to provide optimal care.
View Article and Find Full Text PDF

Purpose: In early-stage hepatocellular carcinoma (HCC) patients merely fit for surgery, transarterial chemoembolization (TACE) achieve low long-term disease control. We evaluated the efficacy and safety of its combination with moderately hypofractionated radiotherapy (hRT) using RTF3 regimen.

Material And Methods: Between 2006 and 2016, 61 consecutive patients treated in our single expert center for a Barcelona Clinic Liver Cancer (BCLC) A HCC by TACE followed by hRT 3Gy/fraction were retrospectively included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!